Free Trial

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bank of New York Mellon Corp

Harmony Biosciences logo with Medical background
Remove Ads

Bank of New York Mellon Corp grew its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 265,639 shares of the company's stock after purchasing an additional 32,272 shares during the period. Bank of New York Mellon Corp owned approximately 0.47% of Harmony Biosciences worth $9,141,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its holdings in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after acquiring an additional 965 shares during the last quarter. KBC Group NV lifted its holdings in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after acquiring an additional 819 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences in the 3rd quarter valued at about $74,000. Finally, Avanza Fonder AB bought a new stake in Harmony Biosciences in the fourth quarter worth about $145,000. Hedge funds and other institutional investors own 86.23% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. HC Wainwright decreased their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Finally, Mizuho lifted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $53.33.

Check Out Our Latest Report on Harmony Biosciences

Insider Activity

In other news, CFO Sandip Kapadia sold 25,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey Dierks sold 1,123 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock valued at $2,831,679 over the last ninety days. 30.80% of the stock is currently owned by insiders.

Harmony Biosciences Stock Up 1.3 %

NASDAQ HRMY traded up $0.46 on Tuesday, hitting $34.78. The stock had a trading volume of 826,786 shares, compared to its average volume of 514,999. The business's fifty day moving average price is $36.40 and its 200 day moving average price is $35.62. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same period in the previous year, the company earned $0.45 earnings per share. The business's revenue for the quarter was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Recommended Stories

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Should You Invest $1,000 in Harmony Biosciences Right Now?

Before you consider Harmony Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.

While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads